Clinical Trial

Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol

Study acronym: ENGAGE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
ENGAGE (Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol) is a Phase 3, randomized, double-blind, placebo-controlled, multicenter trial to assess the efficacy and safety of solriamfetol for the treatment of binge eating disorder (BED) in adults.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2025-12 -> 2026-12 2026-07-29
minor Completion pushed: 2025-12 -> 2026-12 2026-07-29
Trial Details
NCT Number NCT06413433
Lead Sponsor Axsome Therapeutics, Inc.
Conditions Binge-Eating Disorder
Enrollment 450 participants
Start Date 2024-04-26
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-28